# The Safety and Effectiveness of a Two-Drug Combination in the Treatment of Patients With Hepatitis C Plus Advanced HIV Infections

> **NCT00001035** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 10 (—)

## Conditions studied

- HIV Infections
- Hepatitis C

## Interventions

- **DRUG:** Interferon alfa-2b
- **DRUG:** Zidovudine
- **DRUG:** Zalcitabine
- **DRUG:** Didanosine

## Key facts

- **NCT ID:** NCT00001035
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 1996-09
- **Target enrollment:** 10 (—)
- **Last updated:** 2012-04-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001035, "The Safety and Effectiveness of a Two-Drug Combination in the Treatment of Patients With Hepatitis C Plus Advanced HIV Infections". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00001035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*